Gsa Capital Partners LLP Allogene Therapeutics, Inc. Transaction History

Gsa Capital Partners LLP

14 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2024 Aug 15, 2024	BUY	$2.23 - $4.38 $1.86 Million - $3.66 Million	835,342 New	835,342 $1.95 Million
Q4 2023 Feb 16, 2024	SELL	$2.28 - $3.5 $242,350 - $372,029	-106,294 Reduced 83.82%	20,518 $65,000
Q3 2023 Nov 15, 2023	BUY	$3.17 - $5.96 $401,994 - $755,799	126,812 New	126,812 $401,000
Q4 2022 Feb 13, 2023	BUY	$5.62 - $11.11 $1.23 Million - $2.44 Million	219,538 Added 689.37%	251,384 $1.58 Million
Q3 2022 Nov 14, 2022	BUY	$10.32 - $17.28 $328,650 - $550,298	31,846 New	31,846 $344,000
Q2 2022 Aug 09, 2022	SELL	$6.78 - $12.28 $1.01 Million - $1.83 Million	-148,804 Closed	0 $0
Q1 2022 May 11, 2022	BUY	$7.65 - $15.29 $260,015 - $519,691	33,989 Added 29.6%	148,804 $1.36 Million
Q4 2021 Feb 14, 2022	BUY	$13.13 - $24.52 $1.51 Million - $2.82 Million	114,815 New	114,815 $1.71 Million
Q3 2021 Nov 12, 2021	SELL	$21.01 - $27.64 $293,110 - $385,605	-13,951 Closed	0 $0
Q2 2021 Aug 05, 2021	BUY	$23.49 - $35.8 $327,708 - $499,445	13,951 New	13,951 $364,000
Q1 2021 May 10, 2021	SELL	$25.79 - $39.02 $290,730 - $439,872	-11,273 Closed	0 $0
Q4 2020 Feb 03, 2021	BUY	$25.24 - $43.45 $284,530 - $489,811	11,273 New	11,273 $285,000
Q1 2020 May 12, 2020	SELL	$18.22 - $28.25 $193,532 - $300,071	-10,622 Closed	0 $0
Q4 2019 Feb 12, 2020	BUY	$24.82 - $31.4 $263,638 - $333,530	10,622 New	10,622 $276,000

162

134M

59.4K

113K

Ticker ALLO
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 143,807,008
Market Cap $326M
Description
Allogene Therapeutics, Inc., a clinical stage immuno-oncology company, develops and commercializes genetically engineered allogeneic T cell therapies for the treatment of cancer. It develops, manufactures, and commercializes UCART19, an allogeneic chimeric antigen receptor (CAR) T cell product candidate for the treatment of pediatric and adult p...

Get notified when there are updates to the investment portfolio of Gsa Capital Partners LLP, based on Form 13F filings with the SEC.

Stay updated on Gsa Capital Partners LLP with notifications on news.